IRVINE, Calif.–(BUSINESS WIRE)–Axonics Modulation Technologies, Inc. (Nasdaq: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported results for the fourth quarter and fiscal year ended December 31, 2020.
Raymond W. Cohen, Axonics CEO, said, “In the first year of Axonics’ commercial launch in the United States, we exceeded our ambitious goals despite the pandemic and only having approximately ten months of selling time. We are grateful for the overwhelmingly positive response from physicians and patients to the introduction of our r-SNM System. We look forward to more Americans getting vaccinated and a return to a more normalized elective procedure environment in which we can take full advantage of the strong growth outlook for Axonics and the SNM market.”
Fourth Quarter 2020 Financial Results
Fiscal Year 2020 Financial Results
Clinical and Regulatory Highlights
Webcast and Conference Call
Axonics will host a conference call today, February 25, 2021, at 4:30 p.m. Eastern Time, to discuss financial results and recent business developments. The live teleconference may be accessed by dialing 888-771-4371 (U.S.) or 847-585-4405 (International) and using passcode 50112306.
The live webcast of the conference call may be accessed by visiting the Events & Presentations section of the Axonics investor relations website. The replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Axonics website for 90 days.
About Axonics Modulation Technologies, Inc.
Based in Irvine, Calif, Axonics has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction, and through its acquisition of Bulkamid, offers solutions for patients with stress urinary incontinence. These conditions significantly impact quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe, and another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. Stress urinary incontinence affects an estimated 20 million women in the U.S. Axonics’ clinically proven products are offered at hundreds of medical centers across the U.S. and abroad. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. For more information, visit www.axonics.com.
Forward-Looking Statements
Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Words such as “planned,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Axonics filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.
Axonics Modulation Technologies, Inc. Consolidated Balance Sheets (in thousands, except share and per share data) |
|||||||||
|
December 31, |
||||||||
|
2020 |
|
2019 |
||||||
ASSETS |
|
|
|
||||||
Current assets |
|
|
|
||||||
Cash and cash equivalents |
$ |
241,181 |
|
|
|
$ |
171,082 |
|
|
Short-term investments |
— |
|
|
|
12,592 |
|
|
||
Accounts receivable, net of allowance for doubtful accounts of $465 and $75 at December 31, 2020 and 2019, respectively |
18,270 |
|
|
|
7,879 |
|
|
||
Inventory, net |
63,060 |
|
|
|
15,659 |
|
|
||
Prepaid expenses and other current assets |
5,435 |
|
|
|
4,468 |
|
|
||
Total current assets |
327,946 |
|
|
|
211,680 |
|
|
||
Property and equipment, net |
6,328 |
|
|
|
3,047 |
|
|
||
Intangible asset, net |
196 |
|
|
|
311 |
|
|
||
Other assets |
7,736 |
|
|
|
4,784 |
|
|
||
Total assets |
$ |
342,206 |
|
|
|
$ |
219,822 |
|
|
|
|
|
|
||||||
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
||||||
Current liabilities |
|
|
|
||||||
Accounts payable |
$ |
10,660 |
|
|
|
$ |
5,882 |
|
|
Accrued liabilities |
6,684 |
|
|
|
2,174 |
|
|
||
Accrued compensation and benefits |
5,948 |
|
|
|
3,375 |
|
|
||
Operating lease liability, current portion |
1,280 |
|
|
|
602 |
|
|
||
Debt, net of unamortized debt issuance costs, current portion |
21,110 |
|
|
|
— |
|
|
||
Total current liabilities |
45,682 |
|
|
|
12,033 |
|
|
||
Operating lease liability, net of current portion |
9,154 |
|
|
|
4,450 |
|
|
||
Debt, net of unamortized debt issuance costs |
— |
|
|
|
20,336 |
|
|
||
Total liabilities |
54,836 |
|
|
|
36,819 |
|
|
||
Stockholders’ Equity |
|
|
|
||||||
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized, no shares issued and outstanding at December 31, 2020 and 2019 |
— |
|
|
|
— |
|
|
||
Common stock, par value $0.0001 per share, 50,000,000 shares authorized at December 31, 2020 and 2019; 39,931,030 and 34,110,995 shares issued and outstanding at December 31, 2020 and 2019, respectively |
4 |
|
|
|
3 |
|
|
||
Additional paid-in capital |
522,296 |
|
|
|
363,012 |
|
|
||
Accumulated deficit |
(234,499 |
) |
|
|
(179,584 |
) |
|
||
Accumulated other comprehensive loss |
(431 |
) |
|
|
(428 |
) |
|
||
Total stockholders’ equity |
287,370 |
|
|
|
183,003 |
|
|
||
Total liabilities and stockholders’ equity |
$ |
342,206 |
|
|
|
$ |
219,822 |
|
|
Axonics Modulation Technologies, Inc. Consolidated Statements of Comprehensive Loss (in thousands, except share and per share data) |
|||||||||||||||||||
|
Three Months Ended December 31, |
|
Years Ended December 31, |
||||||||||||||||
|
2020 |
|
|
2019 |
|
|
2020 |
|
|
2019 |
|
||||||||
|
(unaudited) |
|
(unaudited) |
|
|
|
|
||||||||||||
Net revenue |
$ |
34,783 |
|
|
|
$ |
9,946 |
|
|
|
$ |
111,535 |
|
|
|
$ |
13,820 |
|
|
Cost of goods sold |
12,652 |
|
|
|
4,538 |
|
|
|
44,444 |
|
|
|
6,490 |
|
|
||||
Gross profit |
22,131 |
|
|
|
5,408 |
|
|
|
67,091 |
|
|
|
7,330 |
|
|
||||
Operating Expenses |
|
|
|
|
|
|
|
||||||||||||
Research and development |
8,140 |
|
|
|
6,233 |
|
|
|
29,170 |
|
|
|
20,181 |
|
|
||||
General and administrative |
6,588 |
|
|
|
5,537 |
|
|
|
25,551 |
|
|
|
19,076 |
|
|
||||
Sales and marketing |
18,284 |
|
|
|
16,301 |
|
|
|
66,130 |
|
|
|
48,672 |
|
|
||||
Total operating expenses |
33,012 |
|
|
|
28,071 |
|
|
|
120,851 |
|
|
|
87,929 |
|
|
||||
Loss from operations |
(10,881 |
) |
|
|
(22,663 |
) |
|
|
(53,760 |
) |
|
|
(80,599 |
) |
|
||||
Other Income (Expense) |
|
|
|
|
|
|
|
||||||||||||
Interest income |
19 |
|
|
|
474 |
|
|
|
761 |
|
|
|
2,974 |
|
|
||||
Loss on disposal of property and equipment |
(41 |
) |
|
|
— |
|
|
|
(41 |
) |
|
|
— |
|
|
||||
Interest and other expense |
(445 |
) |
|
|
(562 |
) |
|
|
(1,874 |
) |
|
|
(2,309 |
) |
|
||||
Other income (expense), net |
(467 |
) |
|
|
(88 |
) |
|
|
(1,154 |
) |
|
|
665 |
|
|
||||
Loss before income tax expense |
(11,348 |
) |
|
|
(22,751 |
) |
|
|
(54,914 |
) |
|
|
(79,934 |
) |
|
||||
Income tax expense |
— |
|
|
|
— |
|
|
|
1 |
|
|
|
1 |
|
|
||||
Net loss |
(11,348 |
) |
|
|
(22,751 |
) |
|
|
(54,915 |
) |
|
|
(79,935 |
) |
|
||||
Foreign currency translation adjustment |
183 |
|
|
|
153 |
|
|
|
(3 |
) |
|
|
(12 |
) |
|
||||
Comprehensive loss |
$ |
(11,165 |
) |
|
|
$ |
(22,598 |
) |
|
|
$ |
(54,918 |
) |
|
|
$ |
(79,947 |
) |
|
|
|
|
|
|
|
|
|
||||||||||||
Net loss per share, basic and diluted |
$ |
(0.29 |
) |
|
|
$ |
(0.75 |
) |
|
|
$ |
(1.48 |
) |
|
|
$ |
(2.80 |
) |
|
Weighted-average shares used to compute basic and diluted net loss per share |
38,971,859 |
|
|
|
30,374,223 |
|
|
|
36,981,335 |
|
|
|
28,567,302 |
|
|
Contacts
Axonics contact:
Neil Bhalodkar
949-336-5293
IR@axonics.com
Hemogenyx Pharmaceuticals Receives IRB Approval for Phase 1 Clinical Trial of HEMO-CAR-T (HG-CT-1)LONDON, UK /…
SAN DIEGO, CA / ACCESSWIRE / November 21, 2024 / Modular Medical, Inc. (Nasdaq:MODD) ("Modular…
BEVERLY HILLS, CALIFORNIA / ACCESSWIRE / November 21, 2024 / Nicole Garrett, CEO of Under…
HUNTINGTON BEACH, Calif., Nov. 21, 2024 /PRNewswire/ -- Beacon Healthcare Systems, is pleased to announce…
Attributes Revenue Growth to Innovative Partnerships, Strong Team, and Unique Value-Based Care Model NEW YORK,…
Automation That Makes a Difference SUNRISE, Fla., Nov. 21, 2024 /PRNewswire/ -- When it comes…